RA
KYTX icon

RFG Advisory’s Kyverna Therapeutics KYTX Stock Holding History

RFG Advisory’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-445,200
Closed -$4.18M – 1120
2025
Q4 		$4.18M Buy
+445,200
New +$3.31M 0.08% 180

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

RFG Advisory's KYTX Position: Q1 2026 in Review

RFG Advisory sold out of Kyverna Therapeutics (KYTX) in Q1 2026, closing a stake of 445,200 shares — an estimated $4.18M sold.

RFG Advisory first reported a position in KYTX in Q4 2025 and held it in 1 quarter. The position peaked at $4.18M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • RFG Advisory reported no remaining Kyverna Therapeutics position as of Q1 2026 after selling out during the quarter.
  • RFG Advisory sold 445,200 Kyverna Therapeutics shares in Q1 2026, an estimated $4.18M.
  • RFG Advisory first reported a position in Kyverna Therapeutics in Q4 2025 and held it in 1 quarter.
  • RFG Advisory's Kyverna Therapeutics position peaked at $4.18M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on RFG Advisory's 13F filing for Q1 2026, filed 20 Apr 2026.